Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
STLE Annual MeetingSTLE Annual Meeting
Not Confirmed
Not Confirmed
18-22 May, 2025
American Thoracic Soci...American Thoracic Society
Not Confirmed
Not Confirmed
18-21 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
STLE Annual MeetingSTLE Annual Meeting
Industry Trade Show
Not Confirmed
18-22 May, 2025
American Thoracic Soci...American Thoracic Society
Industry Trade Show
Not Confirmed
18-21 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions
14 May 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/iteos-gsk-discontinue-lung-cancer-therapy-development-2025-05-13/
28 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/28/3069675/0/en/iTeos-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html
25 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/25/3049201/0/en/iTeos-to-Present-Preclinical-Data-on-Potential-Best-In-Class-Anti-TREM2-Antibody-EOS-215-and-Novel-PTPN1-2-Inhibitor-at-the-American-Association-for-Cancer-Research-Annual-Meeting-.html
05 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/05/3037269/0/en/iTeos-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Updates.html
10 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/10/3007551/0/en/iTeos-Announces-2025-Strategic-Priorities-and-Anticipated-Milestones.html
08 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/08/3006103/0/en/iTeos-to-Present-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference.html
Details:
GSK4057190 (dostarlimab) in combination with GSK4428859A (belrestotug) is currently being evaluated for the treatment of advanced/metastatic non-small-cell lung cancer.
Lead Product(s): Belrestotug,Dostarlimab,Nelistotug
Therapeutic Area: Oncology Brand Name: GSK4428859A
Study Phase: Phase IIProduct Type: Antibody
Sponsor: GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2025
Lead Product(s) : Belrestotug,Dostarlimab,Nelistotug
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
iTeos Shares Interim Results of Belrestotug Combo in PD-L1+ NSCLC Patients
Details : GSK4057190 (dostarlimab) in combination with GSK4428859A (belrestotug) is currently being evaluated for the treatment of advanced/metastatic non-small-cell lung cancer.
Product Name : GSK4428859A
Product Type : Antibody
Upfront Cash : Inapplicable
May 13, 2025
Details:
The net proceeds from the financing are used to advance the clinical development of EOS-448 (belrestotug) in combination with GSK6097608 and Dostarlimab for non-small cell lung cancer.
Lead Product(s): Belrestotug,Dostarlimab,GSK6097608
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IIProduct Type: Antibody
Sponsor: RA Capital Management
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 05, 2024
Lead Product(s) : Belrestotug,Dostarlimab,GSK6097608
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : RA Capital Management
Deal Size : $120.0 million
Deal Type : Public Offering
iTeos Therapeutics Announces $120 Million Registered Direct Offering
Details : The net proceeds from the financing are used to advance the clinical development of EOS-448 (belrestotug) in combination with GSK6097608 and Dostarlimab for non-small cell lung cancer.
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : Undisclosed
October 05, 2024
Details:
EOS-448 (belrestotug, TIGIT antibody) with dostarlimab is being investigated for previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 14, 2024
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
iTeos Reports Positive Objective Response Rate in GALAXIES Lung-201 Study
Details : EOS-448 (belrestotug, TIGIT antibody) with dostarlimab is being investigated for previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : Inapplicable
September 14, 2024
Details:
The collaboration aims to advance the clinical development of late-stage product EOS-448 (belrestotug) in combination with Dostarlimab for the treatment of PD-L1 high Non-small Cell Lung Cancer.
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase II/ Phase IIIProduct Type: Antibody
Sponsor: GSK
Deal Size: $2,075.0 million Upfront Cash: $625.0 million
Deal Type: Collaboration August 07, 2024
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : $2,075.0 million
Deal Type : Collaboration
iTeos Doses First Patient in GALAXIES Lung-301 Phase 3, Earns $35M from GSK
Details : The collaboration aims to advance the clinical development of late-stage product EOS-448 (belrestotug) in combination with Dostarlimab for the treatment of PD-L1 high Non-small Cell Lung Cancer.
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : $625.0 million
August 07, 2024
Details:
EOS-984 is a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 (ENT1). It is being evaluated for the treatment of triple negative breast cancer.
Lead Product(s): EOS-984
Therapeutic Area: Oncology Brand Name: EOS-984
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 04, 2024
Lead Product(s) : EOS-984
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
iTeos Presents EOS-984 Preclinical Data Showing T Cell Activity Restoration
Details : EOS-984 is a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 (ENT1). It is being evaluated for the treatment of triple negative breast cancer.
Product Name : EOS-984
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2024
Details:
Antibody combination, EOS-448 (belrestotug) with dostarlimab is being investigated in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 17, 2024
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
iTeos and GSK Launch Phase 3 Study on Belrestotug and Dostarlimab in Lung Cancer
Details : Antibody combination, EOS-448 (belrestotug) with dostarlimab is being investigated in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : Inapplicable
June 17, 2024
Details:
In preclinical studies and in blood samples from patients with cancer, treatment with EOS-448 (GSK4428859A) results reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune system effector functions.
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IIProduct Type: Antibody
Sponsor: GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 04, 2022
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In preclinical studies and in blood samples from patients with cancer, treatment with EOS-448 (GSK4428859A) results reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune syst...
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : Inapplicable
August 04, 2022
Details:
Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed.
Lead Product(s): Belrestotug
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 04, 2021
Details : Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed.
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : Inapplicable
October 04, 2021
Details:
The addition of EOS-448 results in GSK being the only company with antibodies targeting all three known checkpoints – TIGIT (via EOS-448), CD96 (via GSK’608), and PVRIG (via GSK’562).
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IProduct Type: Antibody
Sponsor: GSK
Deal Size: $2,075.0 million Upfront Cash: $625.0 million
Deal Type: Collaboration June 14, 2021
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : GSK
Deal Size : $2,075.0 million
Deal Type : Collaboration
GSK Pays Up Big for Rights To TIGIT-Targeted Cancer Immunotherapy from Iteos
Details : The addition of EOS-448 results in GSK being the only company with antibodies targeting all three known checkpoints – TIGIT (via EOS-448), CD96 (via GSK’608), and PVRIG (via GSK’562).
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : $625.0 million
June 14, 2021
Details:
The company's lead candidate EOS-850, a highly selective small molecule antagonist of the adenosine A2a receptor (A2AR), is in an open-label Phase 1/2 clinical trial in adult patients with advanced solid tumors, with initial data expected in the 1H 2021.
Lead Product(s): EOS-850
Therapeutic Area: Oncology Brand Name: EOS-850
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Undisclosed
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 24, 2020
Lead Product(s) : EOS-850
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $100.0 million
Deal Type : Public Offering
Phase 1/2 oncology biotech iTeos Therapeutics files for a $100 million IPO
Details : The company's lead candidate EOS-850, a highly selective small molecule antagonist of the adenosine A2a receptor (A2AR), is in an open-label Phase 1/2 clinical trial in adult patients with advanced solid tumors, with initial data expected in the 1H 2021.
Product Name : EOS-850
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 24, 2020
ABOUT THIS PAGE